Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil E Fleshner

Showing results (241-250 of 260) with videos related to

Pageof 26
Sort By:
The Journal of Urology|October 29, 2024
Long-Term Recurrence Risk, Metastatic Potential, and Length of Cystoscopic Surveillance of Low-Grade Nonmuscle-Invasive Bladder CancerEunice Villegas, Katherine Lajkosz, Shayan Din, et al.
BJU International|May 26, 2025
Impact of concomitant carcinoma in situ distribution on non-muscle-invasive bladder cancer progression riskJethro C C Kwong, Keiran Pace, Zizo Al-Daqqaq, et al.
The American Journal of Surgical Pathology|August 19, 2008
Interobserver variability between expert urologic pathologists for extraprostatic extension and surgical margin status in radical prostatectomy specimensAndrew J Evans, Pauline C Henry, Theodorus H Van der Kwast, et al.
The Journal of Urology|August 29, 2018
International Multicenter Validation of an Intermediate Risk Subclassification of Prostate Cancer Managed with Radical Treatment without Hormone TherapyAlejandro Berlin, Fabio Y Moraes, Noelia Sanmamed, et al.
Journal of the National Cancer Institute|April 5, 2017
Germline Mutations in the Kallikrein 6 Region and Predisposition for Aggressive Prostate CancerLaurent Briollais, Hilmi Ozcelik, Jingxiong Xu, et al.
The Lancet. Digital Health|May 21, 2023
Development, multi-institutional external validation, and algorithmic audit of an artificial intelligence-based Side-specific Extra-Prostatic Extension Risk Assessment tool (SEPERA) for patients undergoing radical prostatectomy: a retrospective cohort studyJethro C C Kwong, Adree Khondker, Eric Meng, et al.
The Lancet. Oncology|May 15, 2023
Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysisAlexandre R Zlotta, Leslie K Ballas, Andrzej Niemierko, et al.
Journal of the National Cancer Institute|January 20, 2005
Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT)Scott M Lippman, Phyllis J Goodman, Eric A Klein, et al.
European Urology|October 8, 2025
Development and International Evaluation of an Artificial Intelligence-based Model (PROGRxN-BCa) Using the World Health Organization 2004/2022 Grading System to Predict Progression Risk and Improve Substratification for Non-muscle-invasive Bladder CancerJethro C C Kwong, Zizo Al-Daqqaq, Yashan Chelliahpillai, et al.
European Urology|July 2, 2015
Development of a Standardized Set of Patient-centered Outcomes for Advanced Prostate Cancer: An International Effort for a Unified ApproachAlicia K Morgans, Annelotte C M van Bommel, Caleb Stowell, et al.
Pageof 26

Showing results (241-250 of 260) with videos related to

Sort By:
Pageof 26
The Journal of Urology|October 29, 2024
Long-Term Recurrence Risk, Metastatic Potential, and Length of Cystoscopic Surveillance of Low-Grade Nonmuscle-Invasive Bladder CancerEunice Villegas, Katherine Lajkosz, Shayan Din, et al.
BJU International|May 26, 2025
Impact of concomitant carcinoma in situ distribution on non-muscle-invasive bladder cancer progression riskJethro C C Kwong, Keiran Pace, Zizo Al-Daqqaq, et al.
The American Journal of Surgical Pathology|August 19, 2008
Interobserver variability between expert urologic pathologists for extraprostatic extension and surgical margin status in radical prostatectomy specimensAndrew J Evans, Pauline C Henry, Theodorus H Van der Kwast, et al.
The Journal of Urology|August 29, 2018
International Multicenter Validation of an Intermediate Risk Subclassification of Prostate Cancer Managed with Radical Treatment without Hormone TherapyAlejandro Berlin, Fabio Y Moraes, Noelia Sanmamed, et al.
Journal of the National Cancer Institute|April 5, 2017
Germline Mutations in the Kallikrein 6 Region and Predisposition for Aggressive Prostate CancerLaurent Briollais, Hilmi Ozcelik, Jingxiong Xu, et al.
The Lancet. Digital Health|May 21, 2023
Development, multi-institutional external validation, and algorithmic audit of an artificial intelligence-based Side-specific Extra-Prostatic Extension Risk Assessment tool (SEPERA) for patients undergoing radical prostatectomy: a retrospective cohort studyJethro C C Kwong, Adree Khondker, Eric Meng, et al.
The Lancet. Oncology|May 15, 2023
Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysisAlexandre R Zlotta, Leslie K Ballas, Andrzej Niemierko, et al.
Journal of the National Cancer Institute|January 20, 2005
Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT)Scott M Lippman, Phyllis J Goodman, Eric A Klein, et al.
European Urology|October 8, 2025
Development and International Evaluation of an Artificial Intelligence-based Model (PROGRxN-BCa) Using the World Health Organization 2004/2022 Grading System to Predict Progression Risk and Improve Substratification for Non-muscle-invasive Bladder CancerJethro C C Kwong, Zizo Al-Daqqaq, Yashan Chelliahpillai, et al.
European Urology|July 2, 2015
Development of a Standardized Set of Patient-centered Outcomes for Advanced Prostate Cancer: An International Effort for a Unified ApproachAlicia K Morgans, Annelotte C M van Bommel, Caleb Stowell, et al.
Pageof 26